Quote:

---

Lilly clearly thinks its drug --which failed two earlier late-stage studies only to see Lilly double down, convinced that a second look at the data pointed to a clear clinical pathway that would lead it to one of the Holy Grails of drug research-- is going to fail at significantly improving function.
..... there has not been a successful AD program since the last approval for memantine and they are betting on negotiating an approval based on a single primary cognitive endpoint since they will be the first to file after the negative readout of bapineuzumab in 2012.

---